PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Neurocrine Biosciences, Inc. for the ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

Accurate interpretation of electrolyte blood results is key to patient diagnosis and management. Read our guide.

Have you been diagnosed with Adrenal tumour? Here are the top 10 signs that will help you know if its cancerous or not!

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company that says it is “pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of ... pediatric ...

Neurocrine’s Crenessity approval for CAH treatment represents a transformative opportunity. See why I maintain my strong buy ...

Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...

Neurocrine Biosciences stock jumped Monday after the company won FDA approval for the first new treatment for an adrenal ...

Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for ...

Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel ...